Literature DB >> 16169762

Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta2-agonist.

Sverre Lehmann1, Per Sigvald Bakke, Geir Egil Eide, Sjur Humerfelt, Amund Gulsvik.   

Abstract

Normative cut-off values for the bronchodilator reversibility test are published neglecting factors that may influence the test result other than disease. The objective of this cross-sectional study of a general population was to examine how a salbutamol reversibility test response is depending on anthropometrical variables and smoking. An age and gender stratified random sample of all adults aged 47-48 and 71-73 years living in Bergen, Norway, was invited. The 3506 attendants (69%) filled in a questionnaire and performed spirometry before and after inhalation of 400 microg salbutamol. The mean (SD) absolute FEV(1) bronchodilator response, the change in % predicted, and the change in % initial among middle-aged were 71 (122) ml, 2.0 (3.3)%, and 2.4 (4.1)%, and in the elderly 64 (113) ml, 2.4 (4.3)% and 3.3 (5.9)%, respectively. In a multiple linear regression analysis including adjustment for the initial FEV1 in % predicted, smoking and pack-years were negatively correlated to all indices. Current smoking was considerably more important than past smoking. Female gender, old age, and BMI were positively correlated with the percentage change indices, but the correlation with BMI decreased with increasing heights. These trends were unchanged after excluding subjects with obstructive lung disease or coronary heart disease. This study demonstrates that smoking habits predict all indices expressing the salbutamol bronchodilator response among middle-aged and elderly from a general population. Also, the change in % predicted and the change in % initial indices are dependent on anthropometrical variables. However, although smoking and anthropometrical variables, as well as level of lung function predict the response to inhaled beta2-agonists, these factors explain only 7-16% of the total variation of the measurement indices, and seem therefore of minor importance to the interpretation of the test result.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16169762     DOI: 10.1016/j.pupt.2005.07.006

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  9 in total

Review 1.  Asthma Pharmacogenomics: 2015 Update.

Authors:  Joshua S Davis; Scott T Weiss; Kelan G Tantisira
Journal:  Curr Allergy Asthma Rep       Date:  2015-07       Impact factor: 4.806

2.  A genome-wide association study of bronchodilator response in participants of European and African ancestry from six independent cohorts.

Authors:  Jessica D Gereige; Hanfei Xu; Victor E Ortega; Michael H Cho; Ming Liu; Phuwanat Sakornsakolpat; Edwin K Silverman; Terri H Beaty; Bruce E Miller; Per Bakke; Amund Gulsvik; Craig P Hersh; Jarrett D Morrow; Elizabeth J Ampleford; Gregory A Hawkins; Eugene R Bleecker; Deborah A Meyers; Stephen P Peters; Juan C Celedón; Kelan Tantisira; Jiang Li; Josée Dupuis; George T O'Connor
Journal:  ERJ Open Res       Date:  2022-06-27

3.  Genetic association analysis of COPD candidate genes with bronchodilator responsiveness.

Authors:  Woo Jin Kim; Craig P Hersh; Dawn L DeMeo; John J Reilly; Edwin K Silverman
Journal:  Respir Med       Date:  2008-12-25       Impact factor: 3.415

4.  Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study.

Authors:  Wan C Tan; William M Vollmer; Bernd Lamprecht; David M Mannino; Anamika Jithoo; Ewa Nizankowska-Mogilnicka; Filip Mejza; Thorarinn Gislason; Peter G J Burney; A Sonia Buist
Journal:  Thorax       Date:  2012-04-29       Impact factor: 9.139

5.  Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups.

Authors:  B Padhukasahasram; J J Yang; A M Levin; M Yang; E G Burchard; R Kumar; P-Y Kwok; M A Seibold; D E Lanfear; L K Williams
Journal:  Pharmacogenomics J       Date:  2014-01-14       Impact factor: 3.550

6.  Airflow limitation as a risk factor for low bone mineral density and hip fracture.

Authors:  Trine Herland; Ellen M Apalset; Geir Egil Eide; Grethe S Tell; Sverre Lehmann
Journal:  Eur Clin Respir J       Date:  2016-10-11

7.  Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study.

Authors:  Polychronis Malliotakis; Manolis Linardakis; George Gavriilidis; Dimitris Georgopoulos
Journal:  Crit Care       Date:  2008-11-14       Impact factor: 9.097

8.  Validity of a questionnaire-based diagnosis of chronic obstructive pulmonary disease in a general population-based study.

Authors:  Nicola Murgia; Jonas Brisman; Annika Claesson; Giacomo Muzi; Anna-Carin Olin; Kjell Torén
Journal:  BMC Pulm Med       Date:  2014-03-21       Impact factor: 3.317

9.  Predicting treatable traits for long-acting bronchodilators in patients with stable COPD.

Authors:  Jieun Kang; Ki Tae Kim; Ji-Hyun Lee; Eun Kyung Kim; Tae-Hyung Kim; Kwang Ha Yoo; Jae Seung Lee; Woo Jin Kim; Ju Han Kim; Yeon-Mok Oh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.